Newsletter April 2026
Join us at ACCR San Diego for a fun evening reception and stop by our posters
Dear Colleague,
Will you be attending AACR in San Diego this year?
We would be delighted to welcome you to our exclusive evening reception on Sunday, April 19th, at the East Village Brewing Company in downtown San Diego.
Starting at 6PM, we will open the evening with welcome drinks and a brief introduction to EPO’s latest scientific developments in preclinical oncology. Afterwards, we invite you to enjoy excellent food and craft beverages while connecting with peers and the EPO team in a relaxed atmosphere.
As space is limited, please reserve your place by contacting Turn on Javascript!.
In addition, our scientists will be presenting new data during the poster sessions. Please feel free to contact Jens Hoffmann to arrange a meeting, or simply stop by to meet the team. We would be delighted to discuss how EPO’s advanced preclinical tumor models can support your development program. We look forward to seeing you in San Diego!
Warm regards, The EPO Team
EPO POSTER PRESENTATIONS at AACR 2026
Title Enhanced in vivo and ex vivo analysis enables deeper characterization of humanized mouse models for immuno-oncology research
Presented by Maria Stecklum
Poster #714 - Board 4 - Section 29 – Session: Molecular Pathology on 4/19/2026 at 2PM – 5PM
Title Humanized mouse models 2.0 - Improved
preclinical evaluation of novel immune cell therapies, check point
inhibitors, and immune cell engagers by excluding false positive or
negative results
Presented by Maria Stecklum
Poster #3385 - Board 15 - Section 27 – Session: Humanized Mouse Models on 4/20/2026 at 2PM – 5PM
Title Modeling the multicellular blood-brain barrier
with a PDX-derived glioblastoma microenvironment: comparing human and
mouse biochip systems for tumor heterogeneity and drug response
Presented by Amélie Paillereau (Dynamic42); first author Michelle Zimmer (EPO)
Poster #3401 - Board 6 - Section 28 – Session: In Vitro Models 1: 2D and 3D on 4/20/2026 at 2PM – 5PM
Title Repurposing PARP inhibitors in molecularly
defined subgroups of peritoneal metastatic colorectal cancer (pmCRC):
Preclinical analysis of patient-derived xenograft (PDX) models
Presented by Antje Wengner
Poster #4476 - Board 24 - Section 13 – Session: Drug Combinations, Repurposing, and Differentiation 4/21/2026 at 9AM – 12PM